INTRODUCTION
Mannitol is a fructose-based sugar alcohol that has been a treatment stalwart for increased intracranial pressure (ICP) in neurocritical illness. Its action is osmotic: when administered intravenously, mannitol increases plasma osmolality, creating an osmotic gradient across the intact blood–brain barrier that promotes the movement of water from the cerebral interstitium into the intravascular compartment1,2). This leads to reduction in cerebral edema, augmentation of cerebral perfusion pressure, along with preventing life-threatening brain herniation2,3). Thus, mannitol is a management of choice used extensively in the disorders of traumatic brain injury, stroke, intracerebral hemorrhage, and perioperative brain edema2,4).
Even though the frequent usage of mannitol and its harmless safety record might suggest it does not come without hazard. The most frequent adverse effect is related to its osmotic action—renal stress, hypovolemia, or electrolyte disturbance3). Yet a less appreciated, potentially lethal complication is IgE-mediated hypersensitivity, like anaphylaxis5,6). Although infrequent, there are several case reports and immunologic studies indicating this fulminant reaction, which can happen in minutes following infusion and may be misattributed to other causes in critically ill patients.
Increasing evidence indicates that cross-reactive carbohydrate determinants (CCDs) comprise the substrate for mannitol-induced allergy. CCDs are glycan motifs found on plant, insect, and fungal glycoproteins that are capable of inducing IgE antibody production in susceptible individuals. The physicochemical characteristics of mannitol can stabilize or increase the presentation of CCDs to the immune system, facilitating IgE binding and leading to mast cell degranulation. This mechanism, as of now still under research, may be responsible for clumping of mannitol reactions in patients with a history of atopy, increased pollen sensitivities, or food allergy—especially legumes like peanuts and soybeans7,8).
Recognition of this hypersensitivity mechanism is of especial importance to the neurointensivist, as mannitol is so commonly used in emergent cases where diagnostic uncertainty and therapeutic need normally reign. Ignorance of or failure to expect an allergic reaction can lead to unnecessary morbidity or mortality.
This article attempts to condense the immunopathogenesis, clinical data, diagnostic methods, and prevention of mannitol hypersensitivity. We also address the applicability to neurocritical care as well as the promise for the use of hypertonic saline as a replacement in susceptible populations.
PATHOPHYSIOLOGY OF MANNITOL-INDUCED ANAPHYLAXIS
Pharmacology and Molecular Structure
Mannitol (C₆H₁₄O₆) is a six-carbon sugar alcohol, or polyol). It is produced by hydrogenation of fructose9). It is inert chemically in the body, non-metabolizable, and excreted by the kidneys unchanged. Its osmotic effect is the basis of its therapeutic application, especially for decreasing intracranial and intraocular pressure.
While mannitol itself is generally non-immunogenic, it can form stable hydrogen-bonding networks that may facilitate the preservation and presentation of immunologically relevant carbohydrate epitopes. Such interactions can be harnessed in order to stabilize and present some glycan antigens—significantly cross-reactive carbohydrate determinants (CCDs)—to the immune system. While mannitol itself is not a glycoprotein, its presence in formulations with excipients or trace amounts of plant-derived impurities can be exploited in order to immunologically detect CCDs based on the preservation of their conformational integrity in solution10).
Immunological Function of Cross-Reactive Carbohydrate Determinants (CCDs)
CCDs are non-specific carbohydrate groups of glycoproteins of diverse origin such as plants (e.g., grass and tree pollen), insects, and parasites. Exemplary structures are β (1,2)-xylose and core α (1,3)-fucose motifs11). Whereas CCD-specific IgE antibodies occur in a considerable percentage of atopic patients—especially grass pollen or legume allergy patients—such antibodies do not always have to accompany clinical symptoms. But under unusual circumstances, particularly when CCDs are administered in high dose or under conditions that predispose to the activation of the immune response, they can cause systemic allergic reactions, including IgE-mediated anaphylaxis12,13).
The theoretic basis for the anaphylaxis induced by mannitol is thought to involve stabilization or conservation of CCDs in their native state upon intravenous administration. In sensitized patients—those with pre-existing IgE antibodies to CCDs—this may lead to cross-linking of IgE on mast cells and basophils, initiating the release of histamine, tryptase, and other inflammatory mediators. The cascade translates clinically into hypotension, bronchospasm, urticaria, and, in extreme cases, cardiovascular collapse13).
At-Risk Populations
Patients with multiple allergens, especially those with sensitizations to grass pollen (e.g., Gramineae family), legume sensitizations (e.g., peanuts, soybeans), and insect venom sensitizations, seem to be at greater risk. Furthermore, the incidence of intraoperative or preoperative mannitol use, classically as a bolus via central or peripheral lines, accelerates the rate and dose of systemic exposure, possibly augmenting anaphylactic risk13).
Diagnostic Implications
Because of the infrequent occurrence of mannitol anaphylaxis and lack of specificity of intraoperative or ICU anaphylactic presentation (e.g., hypotension, tachycardia, hypoxia), under-diagnosis or misdiagnosis are prevalent. Post hoc diagnosis may be facilitated by elevated serum tryptase, measurement of mannitol-specific IgE (if possible), or basophil activation tests. Skin prick or intradermal testing have been utilized sparingly in individual cases10).
CLINICAL EVIDENCE
Case Reports and Sentinel Events
Although rare, mannitol-induced anaphylaxis has been documented in the literature, with increasing attention to the role of cross-reactive carbohydrate determinants (CCDs) in susceptible individuals.
Roncati et al. (2013)
A sentinel case was reported by Roncati and colleagues. It described a fatal intraoperative anaphylactic reaction following intravenous mannitol administration in a middle-aged patient with known multiple environmental allergies. On the other hand, there was additional involvement of sudden cardiovascular collapse shortly after mannitol infusion. The Autopsy findings revealed widespread mast cell degranulation. Alongside postmortem serological analysis revealed high titers of anti-CCD-specific IgE, supporting an IgE-mediated mechanism. It was an interesting as it raised awareness of the immunogenic potential of mannitol in atopic individuals.
Schmid and Wuthrich (1992)
Schmid and Wüthrich reported a severe peri-anesthetic anaphylactoid reaction in a patient undergoing surgery who had a history of seasonal allergic rhinitis. This patient developed bronchospasm and hypotension shortly after exposure to mannitol, which was administered as part of an intraoperative protocol. Though specific IgE testing was not performed at that time, the clinical presentation suggested a hypersensitivity mechanism10).
Broader Context: CCD-Mediated Hypersensitivity
Commins and Platts-Mills (2009) showed that the broader relevance of CCDs in allergic syndromes, particularly in patients with mammalian meat allergy or reactions to certain vaccines and biological products. In this research it is underscored how non-protein antigens such as glycan structures can serve as clinically significant triggers of anaphylaxis in sensitized individuals10).
IMPLICATIONS FOR NEUROCRITICAL CARE
As per the above cases, though infrequent, they potentiate the severity and rapid progression of mannitol-associated anaphylaxis. The daily use of mannitol in neurocritical care is often administered in emergency situations at high doses. The failure to identify at-risk individuals may lead to fatal outcomes, especially when differential diagnosis of intraoperative hypotension is delayed.
Clinicians should maintain a high index of suspicion in patients who present:
• A history of multiple environmental or food allergies (e.g., grass pollen, legumes, insect stings)
• History of unexplained intraoperative hypotension or flushing, or confirmation of IgE sensitization to CCDs (when tested).
In such conditions hypertonic saline may offer a safer alternative for Intracranial pressure reduction10).
Challenges in Assessing Intracranial Pressure in Preterm Infants
The evaluation of intracranial pressure (ICP) in preterm newborns is complicated by the open fontanels, soft sutances, small ventricular compartments, and the invasiveness associated with the usual methods for monitoring intracranial pressure using most current monitoring systems being invasve. Direct intraventricular monitoring is not usually performed in the preterm infant because of the risk of hemorrhage and associated technical issues associated with these methods. Hence, surrogate measures for monitoring ICP in these newborns include cranial ultrasound findings, optic nerve sheath measurements using two-dimensional imaging techniques, head circumference measurements for recurrence or resolution with time, and other clinical features like apnea, bradycardia, or changes in mental status. Newer methods for neuromonitoring using near-infrared spectroscopy or transcranial Doppler ultrasonography hold promise but need further research for development.
DIAGNOSTIC STRATEGIES
Clinical History and Risk Stratification
A detailed clinical history on allergy is the utmost priority in identifying patients at risk for mannitol-induced hypersensitivity. The following factors should be crucial in identifying high risk individuals:
• Noted and known allergies to pollens, legumes (such as peanuts, soybeans, or lentils), or latex, which are frequently associated with CCD sensitization.
• Most of the atopic conditions such as allergic rhinitis, asthma, eczema or food allergies.
• History of unexplained anaphylaxis or intraoperative cardiovascular instability following exposure to unknown agents.
• Allergic reaction to biological products (e.g., antithymocyte globulin, gelatin-containing vaccines) containing CCDs as stabilizers or excipients (Table 1).
These features may suggest a CCD-mediated hypersensitivity profile, and may need to opt for immunological evaluation preceeding mannitol administration13).
Immunological Testing
Routine testing for mannitol allergy is not standardized yet, but several immunological tools can assist in assessment of high risks:
• Specific IgE testing for common CCD markers (e.g., bromelain, MUXF3, or cross-reactive glycoepitopes found in latex or certain foods). Commercial immunoassays such as ImmunoCAP can detect CCD-specific IgE. Their interpretation requires additional requirement of clinical correlation because of the potential cross-reactivity with irrelevant antigens.
• Basophil Activation Test (BAT), a functional in vitro assay detecting basophil degranulation in response to mannitol exposure. Although sensitive and specific, it is currently limited by availability and cost. It is most probably used in research or specialized allergy centers.
• Skin prick or intradermal testing with mannitol solutions is primarily used in controlled settings. It involves interpretations with precautions. Mannitol can cause non-IgE-mediated dermal irritation, leading to false-positive results. Furthermore, systemic reactions are theoretically possible in highly sensitized patients7,10) (Table 2 and Fig. 1).
MANAGEMENT AND PREVENTION
Acute Management of Mannitol-Induced Anaphylaxis
An early suspicion of mannitol-induced anaphylaxis intraoperatively or in the intensive care unit is must so that quick detection and management is done at the right time. The following additional requirements are also a must:
Immediate cessation of mannitol infusion at the initial signs of hypersensitivity involving hypotension, urticaria, bronchospasm.
Administer intramuscular epinephrine (0.3–0.5 mg) as first-line therapy, with repitation of dose as per requirement.
Supportive Measures
Airway protection and mechanical ventilation if indicated
Intravenous fluids for volume resuscitation
Vasopressors (e.g., norepinephrine) in cases of refractory hypotension
Adjunctive Medications
Antihistamines (e.g., diphenhydramine)
Corticosteroids (e.g., hydrocortisone or methylprednisolone)
Inhaled β₂-agonists for bronchospasm
Prevention Strategies in High-Risk Patients
Before starting osmotherapy, individuals with known or suspected CCD sensitization should take the following precautionary measures:
• Choose hypertonic saline (3% or 23.4%) over mannitol in- Individuals with a history of food allergies, particularly to legumes such as peanuts and soybeans, which are commonly associated with cross-reactive carbohydrate determinant (CCD) sensitization. A focused history of legume food allergy is therefore a practical and clinically relevant screening question for neurointensivists when considering mannitol administration.
• Mannitol should be avoided when specific testing or clinical history suggests prior sensitization.
• In elective surgical cases, a preoperative allergy consultation is required for:
• Clarifying previous unexplained perioperative reactions
• Assessing for desensitization protocols or alternative therapies
Finally, institutional protocols should include mannitol as a potential allergen in electronic medical records and allergy alert systems8,13) (Fig. 3).
Mannitol is considered to be a widely used agent in the intervention of raised intracranial pressure (ICP) in multiple neurocritical conditions, including traumatic brain injury, malignant stroke, and post-neurosurgical edema. However, its potential to trigger life-threatening anaphylactic reactions potentially in patients with preexisting allergic diatheses makes it a requirement in a more optimized approach to use in intensive neurological care.
To reduce this risk, neurocritical care units should implement the following measures:
• Inclusion of CCD risk assessment into standard pre-treatment checklists. History of allergy should include common food and drug allergies along with sensitization to pollens, legumes, peanuts, soy and previous unexplained hypersensitivity reactions.
• Favor hypertonic saline (3% or 23.4%) over mannitol in patients with suspected or confirmed IgE-mediated CCD sensitivity, especially when emergency ICP management is required.
• Institutional awareness and training programs should be conducted to educate physicians, nurses and pharmacists about the rare but serious potential for mannitol-induced anaphylaxis. Early recognition, emergency management protocols, and interdisciplinary communication becomes a crucial step.
COMPARATIVE ADVANTAGES OF HYPERTONIC SALINE
Recent comparative studies indicate that hypertonic saline is as effective or more effective in reducing intracranial pressure than other treatment modalities in a more predictable manner and non-dependent on CCD-related hypersensitivity. The advantages pertaining to intravascular volume expansion, increased intracerebral perfusion pressures, as well as a decreased incidence of rebound intracranial hypertension make it a preferable agent. This is particularly true in cases where there is a suspected hypersensitivity.
CONCLUSIONS
Mannitol-induced anaphylaxis is uncommon but clinically significant, particularly in atopic patients. The immunological mechanism is based on cross-reactivity with CCDs and hypertonic saline offers a secure, efficient substitute. To handle this neglected risk, neurocritical care teams should continue to be watchful, put allergy screening procedures into place and create institutional solutions.
LIMITATIONS
There are certain limitations to this review. First, because the literature on mannitol-induced anaphylaxis is largely observational in the form of individual reports or small series of cases, it is difficult to approximate the true incidence or to make conclusions about causality. Second, the lack of standardized diagnostic criteria, the variable incorporation of immunologic validation of the diagnosis, and the variable reporting of CCD sensitization make it difficult to compare the literature. Third, there may be a bias in the literature toward more clinically dramatic events, leading to an overestimation of the potential risk. Fourth, the lack of prospective studies or standardized allergy screens means that these conclusions are not generalizable. Lastly, despite full searching of the literature databases, because this is a narrative review, it suffers from the same methodologic issues as non-systematic reviews.
FUTURE DIRECTIONS
Future research efforts need to address the role of cross-reactive carbohydrate determinants (CCDs) in the induction of anaphylactic reactions by medications. Profiling for CCDs may allow the at-risk patient to be identified before the procedure of osmotherapy. Also, research comparing the effectiveness of mannitol and hypertonic saline in the treatment of different patient groups may help streamline the treatment plan. The role of the timing and magnitude of the cumulative dose of mannitol may be of prime importance in the prevention of adverse events. Using the concept of CCDs in the perioperative and neurocritical patient care environment may be the way to ensure patient safety in the future.
PDF Links
PubReader
ePub Link
Full text via DOI
Download Citation
